Dr. Lovly is a physician-scientist with a special interest in thoracic malignancies.

She received a B.A. in chemistry from Johns Hopkins University followed by M.D. and Ph.D. degrees as part of the Medical Scientist Training Program at Washington University in St. Louis, MO. She completed her graduate students in the laboratory of Helena Piwnica-Worms, PhD. 

She then completed internal medicine residency and medical oncology subspecialty training at Vanderbilt University. During her medical oncology fellowship, she completed research fellowship in the laboratory of William Pao, MD, PhD. During her final year of fellowship, she was the Jim and Carol O'Hare Chief Fellow.

D. Lovly started on faculty at Vanderbilt in July 2013 as an Assistant Professor of Medicine and Cancer Biology in July 2013. Dr. Lovly's clinical practice focuses primarily on the care of patients with lung cancer. Her laboratory research is directed at understanding and developing improved therapeutic strategies for specific clinically relevant molecular subsets of lung cancer.

She has received independent grant funding from the Damon Runyon Foundation, the V Foundation, LUNGevity, Uniting Against Lung Cancer, AACR, and the Conquer Cancer Foundation of the American Society of Clinical Oncology. She is the author of several peer-reviewed scientific manuscripts, and she is an active member in the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC), and the American Association for Cancer Research (AACR).

Dr. Lovly is also the co-Editor-in Chief for the website, a Vanderbilt initiated, freely available website which aims to provide health care practitioners, patient, and advocates with up-to-date information regarding genetically informed cancer medicine.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. N-[F]-Fluoroacetylcrizotinib: A potentially potent and selective PET tracer for molecular imaging of non-small cell lung cancer. Buck JR, Saleh S, Claus T, Lovly C, Hight MR, Nickels ML, Noor Tantawy M, Charles Manning H (2020) Bioorg Med Chem Lett 30(16): 127257
    › Primary publication · 32631505 (PubMed) · PMC7357882 (PubMed Central)
  2. Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition. Paliouras AR, Buzzetti M, Shi L, Donaldson IJ, Magee P, Sahoo S, Leong HS, Fassan M, Carter M, Di Leva G, Krebs MG, Blackhall F, Lovly CM, Garofalo M (2020) EMBO Mol Med 12(7): e11099
    › Primary publication · 32558295 (PubMed) · PMC7338803 (PubMed Central)
  3. Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer. Lovly CM, Boyd KL, Gonzalez-Ericsson PI, Lowe CL, Brown HM, Hoffman RD, Sterling BC, Kapp ME, Johnson DB, Kopparapu PR, Iams WT, Warren MA, Noto MJ, Rini BI, Jagasia M, Das SR, Balko JM (2020) medRxiv
    › Primary publication · 32511636 (PubMed) · PMC7276992 (PubMed Central)
  4. COVID-19 and immune checkpoint inhibitors: initial considerations. Sullivan RJ, Johnson DB, Rini BI, Neilan TG, Lovly CM, Moslehi JJ, Reynolds KL (2020) J Immunother Cancer 8(1)
    › Primary publication · 32434790 (PubMed) · PMC7246104 (PubMed Central)
  5. Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group. Forde PM, Bonomi P, Shaw A, Blumenthal GM, Ferris A, Patel C, Melemed A, Basu Roy U, Ramamoorthy A, Liu Q, Burns T, Gainor JF, Lovly C, Piotrowska Z, Lehman J, Selig W (2020) Clin Lung Cancer 21(4): 295-307
    › Primary publication · 32201247 (PubMed)
  6. Vitamin D3 Metabolites Demonstrate Prognostic Value in -Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance. Shaurova T, Dy GK, Battaglia S, Hutson A, Zhang L, Zhang Y, Lovly CM, Seshadri M, Goodrich DW, Johnson CS, Hershberger PA (2020) Cancers (Basel) 12(3)
    › Primary publication · 32183160 (PubMed) · PMC7140110 (PubMed Central)
  7. Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC). Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Du L, Hernandez J, Huang V, Waqar SN, Patel S, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, Liang C, Lim LP, Li M, Lovly CM (2019) Ann Oncol : ii48
    › Primary publication · 32131242 (PubMed)
  8. New Approaches to SCLC Therapy: From the Laboratory to the Clinic. Poirier JT, George J, Owonikoko TK, Berns A, Brambilla E, Byers LA, Carbone D, Chen HJ, Christensen CL, Dive C, Farago AF, Govindan R, Hann C, Hellmann MD, Horn L, Johnson JE, Ju YS, Kang S, Krasnow M, Lee J, Lee SH, Lehman J, Lok B, Lovly C, MacPherson D, McFadden D, Minna J, Oser M, Park K, Park KS, Pommier Y, Quaranta V, Ready N, Sage J, Scagliotti G, Sos ML, Sutherland KD, Travis WD, Vakoc CR, Wait SJ, Wistuba I, Wong KK, Zhang H, Daigneault J, Wiens J, Rudin CM, Oliver TG (2020) J Thorac Oncol 15(4): 520-540
    › Primary publication · 32018053 (PubMed) · PMC7263769 (PubMed Central)
  9. The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. Disel U, Madison R, Abhishek K, Chung JH, Trabucco SE, Matos AO, Frampton GM, Albacker LA, Reddy V, Karadurmus N, Benson A, Webster J, Paydas S, Cabanillas R, Nangia C, Ozturk MA, Millis SZ, Pal SK, Wilky B, Sokol ES, Gay LM, Soman S, Ganesan S, Janeway K, Stephens PJ, Zhu VW, Ou SI, Lovly CM, Gounder M, Schrock AB, Ross JS, Miller VA, Klempner SJ, Ali SM (2020) Oncologist 25(1): e39-e47
    › Primary publication · 31604903 (PubMed) · PMC6964135 (PubMed Central)
  10. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA, Du L, Hernandez J, Huang V, Blumenschein GR, Waqar SN, Patel SP, Nieva J, Oxnard GR, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, Liang C, Lim LP, Li M, Lovly CM (2019) J Thorac Oncol 14(11): 1901-1911
    › Primary publication · 31446141 (PubMed) · PMC6823161 (PubMed Central)
  11. Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes. Iams WT, Shiuan E, Meador CB, Roth M, Bordeaux J, Vaupel C, Boyd KL, Summitt IB, Wang LL, Schneider JT, Warner JL, Zhao Z, Lovly CM (2019) J Thorac Oncol 14(11): 1970-1981
    › Primary publication · 31201935 (PubMed) · PMC6823126 (PubMed Central)
  12. Quantifying Drug Combination Synergy along Potency and Efficacy Axes. Meyer CT, Wooten DJ, Paudel BB, Bauer J, Hardeman KN, Westover D, Lovly CM, Harris LA, Tyson DR, Quaranta V (2019) Cell Syst 8(2): 97-108.e16
    › Primary publication · 30797775 (PubMed) · PMC6675406 (PubMed Central)
  13. On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. Brown BP, Zhang YK, Westover D, Yan Y, Qiao H, Huang V, Du Z, Smith JA, Ross JS, Miller VA, Ali S, Bazhenova L, Schrock AB, Meiler J, Lovly CM (2019) Clin Cancer Res 25(11): 3341-3351
    › Primary publication · 30796031 (PubMed) · PMC6548651 (PubMed Central)
  14. Genomic landscape of a metastatic malignant proliferating tricholemmal tumor and its response to PI3K inhibition. Gallant JN, Sewell A, Almodovar K, Wang Q, Dahlman KB, Abramson RG, Kapp ME, Brown BT, Boyd KL, Gilbert J, Cohen DN, Yarbrough WG, Zhao Z, Lovly CM (2019) NPJ Precis Oncol : 5
    › Primary publication · 30793038 (PubMed) · PMC6377617 (PubMed Central)
  15. Correction: An Acquired Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL (2019) Cancer Discov 9(2): 303
    › Primary publication · 30737217 (PubMed)
  16. Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion. Tsou TC, Gowen K, Ali SM, Miller VA, Schrock AB, Lovly CM, Reckamp KL (2019) J Thorac Oncol 14(2): e29-e30
    › Primary publication · 30683295 (PubMed)
  17. Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases. Iams WT, Beckermann KE, Almodovar K, Hernandez J, Vnencak-Jones C, Lim LP, Raymond CK, Horn L, Lovly CM (2019) J Thorac Oncol 14(3): e45-e48
    › Primary publication · 30543839 (PubMed) · PMC6382512 (PubMed Central)
  18. Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. Yu HA, Planchard D, Lovly CM (2018) Am Soc Clin Oncol Educ Book : 726-739
    › Primary publication · 30231382 (PubMed)
  19. ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. Childress MA, Himmelberg SM, Chen H, Deng W, Davies MA, Lovly CM (2018) Mol Cancer Res 16(11): 1724-1736
    › Primary publication · 30002191 (PubMed) · PMC6214753 (PubMed Central)
  20. Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived. Iams WT, Lovly CM (2018) Cancer Discov 8(7): 797-799
    › Primary publication · 29967074 (PubMed) · PMC6345252 (PubMed Central)
  21. Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. Panda A, Betigeri A, Subramanian K, Ross JS, Pavlick DC, Ali S, Markowski P, Silk A, Kaufman HL, Lattime E, Mehnert JM, Sullivan R, Lovly CM, Sosman J, Johnson DB, Bhanot G, Ganesan S (2017) JCO Precis Oncol
    › Primary publication · 29951597 (PubMed) · PMC6016848 (PubMed Central)
  22. amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S, Yu HA, Jordan EJ, Paik PK, Janjigian YY, Chaft JE, Wang L, Jungbluth AA, Middha S, Spraggon L, Qiao H, Lovly CM, Kris MG, Riely GJ, Politi K, Varmus H, Ladanyi M (2018) Proc Natl Acad Sci U S A 115(26): E6030-E6038
    › Primary publication · 29875142 (PubMed) · PMC6042104 (PubMed Central)
  23. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA (2018) Clin Cancer Res 24(12): 2771-2779
    › Primary publication · 29563138 (PubMed) · PMC6004248 (PubMed Central)
  24. Mechanisms of receptor tyrosine kinase activation in cancer. Du Z, Lovly CM (2018) Mol Cancer 17(1): 58
    › Primary publication · 29455648 (PubMed) · PMC5817791 (PubMed Central)
  25. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou SI (2018) J Clin Oncol 36(12): 1199-1206
    › Primary publication · 29373100 (PubMed) · PMC5903999 (PubMed Central)
  26. Established, emerging and elusive molecular targets in the treatment of lung cancer. Gallant JN, Lovly CM (2018) J Pathol 244(5): 565-577
    › Primary publication · 29344953 (PubMed)
  27. BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy. Johnson DB, Childress MA, Chalmers ZR, Frampton GM, Ali SM, Rubinstein SM, Fabrizio D, Ross JS, Balasubramanian S, Miller VA, Stephens PJ, Sosman JA, Lovly CM (2018) Pigment Cell Melanoma Res 31(3): 432-436
    › Primary publication · 29171936 (PubMed) · PMC5889338 (PubMed Central)
  28. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse. Almodovar K, Iams WT, Meador CB, Zhao Z, York S, Horn L, Yan Y, Hernandez J, Chen H, Shyr Y, Lim LP, Raymond CK, Lovly CM (2018) J Thorac Oncol 13(1): 112-123
    › Primary publication · 28951314 (PubMed) · PMC5827950 (PubMed Central)
  29. Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. Ou SI, Horn L, Cruz M, Vafai D, Lovly CM, Spradlin A, Williamson MJ, Dagogo-Jack I, Johnson A, Miller VA, Gadgeel S, Ali SM, Schrock AB (2017) Lung Cancer : 61-64
    › Primary publication · 28838400 (PubMed)
  30. Managing Resistance to EFGR- and ALK-Targeted Therapies. Lovly CM, Iyengar P, Gainor JF (2017) Am Soc Clin Oncol Educ Book : 607-618
    › Primary publication · 28561721 (PubMed)
  31. SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Ichihara E, Westover D, Meador CB, Yan Y, Bauer JA, Lu P, Ye F, Kulick A, de Stanchina E, McEwen R, Ladanyi M, Cross D, Pao W, Lovly CM (2017) Cancer Res 77(11): 2990-3000
    › Primary publication · 28416483 (PubMed) · PMC5467531 (PubMed Central)
  32. An Acquired Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL (2017) Cancer Discov 7(6): 575-585
    › Primary publication · 28274957 (PubMed) · PMC5457707 (PubMed Central)
  33. Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therapy in Lung Cancer. Qiao H, Lovly CM (2016) Cancer Discov 6(10): 1084-1086
    › Primary publication · 27698100 (PubMed) · PMC5117458 (PubMed Central)
  34. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, Ali SM, Balasubramanian S, Sun JX, He Y, Frederick DT, Puzanov I, Balko JM, Cates JM, Ross JS, Sanders C, Robins H, Shyr Y, Miller VA, Stephens PJ, Sullivan RJ, Sosman JA, Lovly CM (2016) Cancer Immunol Res 4(11): 959-967
    › Primary publication · 27671167 (PubMed) · PMC5134329 (PubMed Central)
  35. My Cancer Genome: Evaluating an Educational Model to Introduce Patients and Caregivers to Precision Medicine Information. Kusnoor SV, Koonce TY, Levy MA, Lovly CM, Naylor HM, Anderson IA, Micheel CM, Chen SC, Ye F, Giuse NB (2016) AMIA Jt Summits Transl Sci Proc : 112-21
    › Primary publication · 27570660 (PubMed) · PMC5001739 (PubMed Central)
  36. Major milestones in translational oncology. Dragani TA, Castells A, Kulasingam V, Diamandis EP, Earl H, Iams WT, Lovly CM, Sedelaar JP, Schalken JA (2016) BMC Med 14(1): 110
    › Primary publication · 27469586 (PubMed) · PMC4964079 (PubMed Central)
  37. Melanoma driver mutations and immune therapy. Johnson DB, Lovly CM, Sullivan RJ, Carvajal RD, Sosman JA (2016) Oncoimmunology 5(5): e1051299
    › Primary publication · 27467925 (PubMed) · PMC4910708 (PubMed Central)
  38. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen L, Scheel AH, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, Schildhaus HU, Fassunke J, Ihle MA, Pasternack H, Heydt C, Becker C, Altmüller J, Ji H, Müller C, Florin A, Heuckmann JM, Nuernberg P, Ansén S, Heukamp LC, Berg J, Pao W, Peifer M, Buettner R, Wolf J, Thomas RK, Sos ML (2016) Clin Cancer Res 22(19): 4837-4847
    › Primary publication · 27252416 (PubMed)
  39. Tumor Heterogeneity and Therapeutic Resistance. Lovly CM, Salama AK, Salgia R (2016) Am Soc Clin Oncol Educ Book : e585-93
    › Primary publication · 27249771 (PubMed)
  40. EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, Ichihara E, Owonikoko TK, Peddareddigari V, Ramalingam SS, Reddy SK, Eaby-Sandy B, Vavalà T, Whiteley A, Chen H, Yan Y, Sheehan JH, Meiler J, Morosini D, Ross JS, Stephens PJ, Miller VA, Ali SM, Lovly CM (2016) Cancer Discov 6(6): 601-11
    › Primary publication · 27102076 (PubMed) · PMC4893907 (PubMed Central)
  41. The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome. Taylor AD, Micheel CM, Anderson IA, Levy MA, Lovly CM (2016) Transl Oncol 9(2): 163-165
    › Primary publication · 27084433 (PubMed) · PMC4833964 (PubMed Central)
  42. Guiding Oncology Patients Through the Maze of Precision Medicine. Giuse NB, Kusnoor SV, Koonce TY, Naylor HM, Chen SC, Blasingame MN, Anderson IA, Micheel CM, Levy MA, Ye F, Lovly CM (2016) J Health Commun : 5-17
    › Primary publication · 27043753 (PubMed) · PMC4910693 (PubMed Central)
  43. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM (2016) Nat Commun : 10582
    › Primary publication · 26822383 (PubMed) · PMC4740184 (PubMed Central)
  44. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆. Hames ML, Chen H, Iams W, Aston J, Lovly CM, Horn L (2016) Lung Cancer : 29-34
    › Primary publication · 26775593 (PubMed) · PMC4874190 (PubMed Central)
  45. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J (2016) Cancer Res 76(2): 305-18
    › Primary publication · 26744526 (PubMed) · PMC4715957 (PubMed Central)
  46. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN (2016) J Clin Oncol 34(2): 123-9
    › Primary publication · 26438117 (PubMed) · PMC5070549 (PubMed Central)
  47. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade. Iams WT, Lovly CM (2015) Clin Cancer Res 21(19): 4270-7
    › Primary publication · 26429980 (PubMed) · PMC4593065 (PubMed Central)
  48. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer. Iams WT, Lovly CM (2015) Cancer J 21(5): 378-82
    › Primary publication · 26389762 (PubMed) · PMC5242382 (PubMed Central)
  49. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG (2015) Nat Med 21(9): 1038-47
    › Primary publication · 26301689 (PubMed) · PMC4734742 (PubMed Central)
  50. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Gallant JN, Sheehan JH, Shaver TM, Bailey M, Lipson D, Chandramohan R, Red Brewer M, York SJ, Kris MG, Pietenpol JA, Ladanyi M, Miller VA, Ali SM, Meiler J, Lovly CM (2015) Cancer Discov 5(11): 1155-63
    › Primary publication · 26286086 (PubMed) · PMC4631701 (PubMed Central)
  51. Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer. Ichihara E, Lovly CM (2015) Cancer Discov 5(7): 694-6
    › Primary publication · 26152920 (PubMed) · PMC4499857 (PubMed Central)
  52. Liquid biopsies reveal the dynamic nature of resistance mechanisms in solid tumors. Meador CB, Lovly CM (2015) Nat Med 21(7): 663-5
    › Primary publication · 26151324 (PubMed)
  53. Combating acquired resistance to tyrosine kinase inhibitors in lung cancer. Lovly CM (2015) Am Soc Clin Oncol Educ Book : e165-73
    › Primary publication · 25993168 (PubMed) · PMC4734636 (PubMed Central)
  54. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Katayama R, Lovly CM, Shaw AT (2015) Clin Cancer Res 21(10): 2227-35
    › Primary publication · 25979929 (PubMed) · PMC4435823 (PubMed Central)
  55. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, Berry EG, Iafrate AJ, Sullivan RJ, Carvajal RD, Sosman JA (2015) Cancer Immunol Res 3(3): 288-295
    › Primary publication · 25736262 (PubMed) · PMC4351797 (PubMed Central)
  56. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, Morgans AK, Puzanov I, Sosman JA, Lovly CM (2015) Cancer Immunol Res 3(5): 464-9
    › Primary publication · 25649350 (PubMed) · PMC4420706 (PubMed Central)
  57. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors. Hornick JL, Sholl LM, Dal Cin P, Childress MA, Lovly CM (2015) Mod Pathol 28(5): 732-9
    › Primary publication · 25612511 (PubMed) · PMC5874150 (PubMed Central)
  58. Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer. Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, Lovly CM, Cross DA, Pao W (2015) Mol Cancer Ther 14(2): 542-52
    › Primary publication · 25477325 (PubMed) · PMC4338015 (PubMed Central)
  59. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, Riely GJ (2015) J Thorac Oncol 10(3): 431-7
    › Primary publication · 25415430 (PubMed) · PMC4479120 (PubMed Central)
  60. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. Venook AP, Arcila ME, Benson AB, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML (2014) J Natl Compr Canc Netw 12(11): 1629-49
    › Primary publication · 25361808 (PubMed) · PMC5241088 (PubMed Central)
  61. MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB, Ladanyi M (2015) Clin Cancer Res 21(8): 1935-43
    › Primary publication · 25351745 (PubMed) · PMC4401580 (PubMed Central)
  62. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Yu HA, Riely GJ, Lovly CM (2014) Clin Cancer Res 20(23): 5898-907
    › Primary publication · 25303979 (PubMed) · PMC4253858 (PubMed Central)
  63. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W (2014) Nat Med 20(9): 1027-34
    › Primary publication · 25173427 (PubMed) · PMC4159407 (PubMed Central)
  64. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Lovly CM, Gupta A, Lipson D, Otto G, Brennan T, Chung CT, Borinstein SC, Ross JS, Stephens PJ, Miller VA, Coffin CM (2014) Cancer Discov 4(8): 889-95
    › Primary publication · 24875859 (PubMed) · PMC4125481 (PubMed Central)
  65. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W (2014) Oncologist 19(6): 616-22
    › Primary publication · 24797823 (PubMed) · PMC4041676 (PubMed Central)
  66. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Lovly CM, Shaw AT (2014) Clin Cancer Res 20(9): 2249-56
    › Primary publication · 24789032 (PubMed) · PMC4029617 (PubMed Central)
  67. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretić L, Seidal D, Zander T, Leenders F, George J, Müller C, Dahmen I, Pinther B, Bosco G, Konrad K, Altmüller J, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soltermann A, Brustugun OT, Helland Å, Solberg S, Lund-Iversen M, Ansén S, Stoelben E, Wright GM, Russell P, Wainer Z, Solomon B, Field JK, Hyde R, Davies MP, Heukamp LC, Petersen I, Perner S, Lovly C, Cappuzzo F, Travis WD, Wolf J, Vingron M, Brambilla E, Haas SA, Buettner R, Thomas RK (2014) Nat Commun : 3518
    › Primary publication · 24670920 (PubMed) · PMC4132974 (PubMed Central)
  68. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W (2014) Clin Cancer Res 20(9): 2264-75
    › Primary publication · 24599935 (PubMed) · PMC4008689 (PubMed Central)
  69. A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. Lammers PE, Lovly CM, Horn L (2014) J Natl Compr Canc Netw 12(1): 6-11; quiz 11
    › Primary publication · 24453288 (PubMed) · PMC4151469 (PubMed Central)